# Paul N Mortenson

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 30 papers | 2,106 citations | 331259 21 h-index | 433756 31 g-index |
| 32 all docs | 32 docs citations | 32 times ranked | 2879 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Diverse, High-Quality Test Set for the Validation of Proteinâ˜Ligand Docking Performance. Journal of Medicinal Chemistry, 2007, 50, 726-741. | 2.9 | 546 |
| 2 | Energy Landscapes: From Clusters to Biomolecules. Advances in Chemical Physics, 2007, , 1-111. | 0.3 | 153 |
| 3 | Proteinâ˜Ligand Docking against Non-Native Protein Conformers. Journal of Chemical Information and Modeling, 2008, 48, 2214-2225. | 2.5 | 129 |
| 4 | Efficient exploration of chemical space by fragment-based screening. Progress in Biophysics and Molecular Biology, 2014, 116, 82-91. | 1.4 | 127 |
| 5 | Docking Performance of Fragments and Druglike Compounds. Journal of Medicinal Chemistry, 2011, 54, 5422-5431. | 2.9 | 109 |
| 6 | Assessing the lipophilicity of fragments and early hits. Journal of Computer-Aided Molecular Design, 2011, 25, 663-667. | 1.3 | 95 |
| 7 | Energy landscapes of model polyalanines. Journal of Chemical Physics, 2002, 117, 1363-1376. | 1.2 | 78 |
| 8 | Energy landscapes, global optimization and dynamics of the polyalanine Ac(ala)8NHMe. Journal of Chemical Physics, 2001, 114, 6443-6454. | 1.2 | 77 |
| 9 | Crystals of binary Lennard-Jones solids. Physical Review B, 2001, 64, . | 1.1 | 77 |
| 10 | Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor. Journal of Medicinal Chemistry, 2010, 53, 8663-8678. | 2.9 | 74 |
| 11 | DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 894-899. | 1.0 | 70 |
| 12 | Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 589-596. | 1.0 | 68 |
| 13 | Fragment-to-Lead Medicinal Chemistry Publications in 2018. Journal of Medicinal Chemistry, 2020, 63, 4430-4444. | 2.9 | 61 |
| 14 | Structureâ€“Activity and Structureâ€“Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1/Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1/NRF2) Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 4683-4702. | 2.9 | 59 |
| 15 | Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 798-803. | 1.3 | 49 |
| 16 | Fragment-to-Lead Medicinal Chemistry Publications in 2017. Journal of Medicinal Chemistry, 2019, 62, 3857-3872. | 2.9 | 47 |
| 17 | Fragment-to-Lead Medicinal Chemistry Publications in 2016. Journal of Medicinal Chemistry, 2018, 61, 1774-1784. | 2.9 | 41 |
| 18 | Fragment-to-Lead Medicinal Chemistry Publications in 2019. Journal of Medicinal Chemistry, 2020, 63, 15494-15507. | 2.9 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors. ACS Medicinal Chemistry Letters, 2012, 3, 445-449. | 1.3 | 34 |
| 20 | Predicting â€œHotâ€•and â€œWarmâ€•Spots for Fragment Binding. Journal of Medicinal Chemistry, 2017, 60, 4036-4046. | 2.9 | 32 |
| 21 | Câ€“H functionalisation tolerant to polar groups could transform fragment-based drug discovery (FBDD). Chemical Science, 2021, 12, 11976-11985. | 3.7 | 30 |
| 22 | ParaMol: A Package for Automatic Parameterization of Molecular Mechanics Force Fields. Journal of Chemical Information and Modeling, 2021, 61, 2026-2047. | 2.5 | 22 |
| 23 | Fragment-Based Discovery of 6-Azaindazoles As Inhibitors of Bacterial DNA Ligase. ACS Medicinal Chemistry Letters, 2013, 4, 1208-1212. | 1.3 | 21 |
| 24 | Allosteric Inhibition of the Neuropeptidase Neurolysin. Journal of Biological Chemistry, 2014, 289, 35605-35619. | 1.6 | 18 |
| 25 | The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 1456-1478. | 1.4 | 17 |
| 26 | Fragment-Based Approaches to the Discovery of Kinase Inhibitors. Methods in Enzymology, 2014, 548, 69-92. | 0.4 | 13 |
| 27 | Identification of orally bioavailable small-molecule inhibitors of hematopoietic prostaglandin D2 synthase using X-ray fragment based drug discovery. MedChemComm, 2014, 5, 134-141. | 3.5 | 8 |
| 28 | The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure. Bioorganic and Medicinal Chemistry, 2020, 28, 115791. | 1.4 | 4 |
| 29 | A knowledge-based, structural-aided discovery of a novel class of 2-phenylimidazo[1,2-a]pyridine-6-carboxamide H-PGDS inhibitors. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128113. | 1.0 | 3 |
| 30 | Generation of Quantum Configurational Ensembles Using Approximate Potentials. Journal of Chemical Theory and Computation, 2021, 17, 7021-7042. | 2.3 | 2 |